Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients

British Journal of Clinical Pharmacology

Volumn 78, Issue 2, 2014, Pages 364-372

  Cusinato, Diego Alberto C ^a   Lacchini, Riccardo ^a   Romao, Elen A ^a   Moysés Neto, Miguel ^a   Coelho, Eduardo B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ABCB1 diplotype; cytochrome P450; kidney transplantation; pharmacogenetics; tacrolimus pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; ABCB1 PROTEIN, HUMAN; CALCINEURIN INHIBITOR; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; BRAZIL; DIPLOTYPE; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HEREDITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; KIDNEY GRAFT; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WILD TYPE; GENETICS; GRAFT REJECTION; KIDNEY TRANSPLANTATION; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE DISTRIBUTION;

ADULT; BRAZIL; CALCINEURIN INHIBITORS; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; GRAFT REJECTION; HAPLOTYPES; HOMOZYGOTE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TACROLIMUS; TISSUE DISTRIBUTION;

EID: 84904880623     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12345     Document Type: Article

References (45)

1. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ,. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 62: 900-905.
2. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thummel KE,. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836-847.
3. Kronbach T, Fischer V, Meyer UA,. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-635.
4. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF,. Cytochrome-P-450 3a enzymes are responsible for biotransformation of fk506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753-761.
5. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T,. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-6080.
6. Zhang YC, Benet LZ,. The gut as a barrier to drug absorption-combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40: 159-168.
7. Thervet E, Anglicheau D, Legendre C, Beaune P,. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit 2008; 30: 143-150.
8. Staatz CE, Goodman LK, Tett SE,. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010; 49: 141-175.
9. Knops N, Levtchenko E, van den Heuvel B, Kuypers D,. From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. Int J Pharm 2013; 452: 14-35.
10. de Jonge H, Kuypers DR,. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev (Orlando) 2008; 22: 6-20.
11. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng AE, Subra JF, Beaune P, Legendre C,. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87: 721-726.
12. Cheung CY, Op den Buijsch RA, Wong KM, Chan HW, Chau KF, Li CS, Leung KT, Kwan TH, de Vrie JE, Wijnen PA, van Dieijen-Visser MP, Bekers O,. Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Pharmacogenomics 2006; 7: 563-574.
13. Fredericks S, Moreton M, Reboux S, Carter ND, Goldberg L, Holt DW, MacPhee IA,. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 2006; 82: 705-708.
14. Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A,. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplant Proc 2008; 40: 1690-1695.
15. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR,. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-199.
16. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, Beaune P, Legendre C, Thervet E,. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889-1896.
17. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG, Pharmacogenetics Membrane T,. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481-494.
18. Salama NN, Yang Z, Bui T, Ho RJY,. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci 2006; 95: 2293-2308.
19. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P,. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-154.
20. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T,. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182-1187.
21. Roy JN, Barama A, Poirier C, Vinet B, Roger M,. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006; 16: 659-665.
22. Chen JS, Li LS, Cheng DR, Ji SM, Sun QQ, Cheng Z, Wen JQ, Sha GZ, Liu ZH,. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. Transplant Proc 2009; 41: 1557-1561.
23. Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB, Suarez-Kurtz G,. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics 2011; 12: 1293-1303.
24. Miller SA, Dykes DD, Polesky HF,. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
25. Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Gridelli B, D'Alessandro N,. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med 2011; 28: 1093-1102.
26. Wu P, Ni X, Wang M, Xu X, Luo G, Jiang Y,. Polymorphisms in CYP3A53 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. Ann Transplant 2011; 16: 54-60.
27. Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J,. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int 2012; 25: 471-480.
28. Stratta P, Quaglia M, Cena T, Antoniotti R, Fenoglio R, Menegotto A, Ferrante D, Genazzani A, Terrazzino S, Magnani C,. The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol 2011; 68: 671-680.
29. Yoon S-H, Cho J-H, Kwon O, Choi J-Y, Park S-H, Kim Y-L, Yoon Y-R, Won D-I, Kim C-D,. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). Transplantation 2013; 95: 828-834.
30. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD,. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci U S A 2003; 100: 177-182.
31. Suarez-Kurtz G, Pena SD, Struchiner CJ, Hutz MH,. Pharmacogenomic diversity among brazilians: influence of ancestry, self-reported color, and geographical origin. Front Pharmacol 2012; 3: 191.
32. Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L, Pena SD, Struchiner C,. Impact of population admixture on the distribution of the CYP3A53 polymorphism. Pharmacogenomics 2007; 8: 1299-1306.
33. Estrela RC, Ribeiro FS, Carvalho RS, Gregorio SP, Dias-Neto E, Struchiner CJ, Suarez-Kurtz G,. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics 2008; 9: 267-276.
34. Ferreira PE, Veiga MI, Cavaco I, Martins JP, Andersson B, Mushin S, Ali AS, Bhattarai A, Ribeiro V, Bjorkman A, Gil JP,. Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit 2008; 30: 10-15.
35. Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, Torresani E, Edefonti A,. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 2010; 62: 1159-1169.
36. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW,. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-1489.
37. MacPhee IA, Fredericks S, Mohamed M, Moreton M, Carter ND, Johnston A, Goldberg L, Holt DW,. Tacrolimus pharmacogenetics: the CYP3A51 allele predicts low dose-normalized tacrolimus blood concentrations in Whites and South Asians. Transplantation 2005; 79: 499-502.
38. Li L, Li CJ, Zheng L, Zhang YJ, Jiang HX, Si-Tu B, Li ZH,. Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study. Eur J Clin Pharmacol 2011; 67: 787-795.
39. Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH, Park SH, Kim YL, Kim CD,. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among korean renal transplant recipients. Transplant Proc 2012; 44: 109-114.
40. Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L,. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene 2013; 512: 226-231.
41. Kim JS, Aviles DH, Silverstein DM, LeBlanc PL, Vehaskari VM,. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005; 9: 162-169.
42. Ferraris JR, Argibay PF, Costa L, Jimenez G, Coccia PA, Ghezzi LF, Ferraris V, Belloso WH, Redal MA, Larriba JM,. Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids. Pediatr Transplant 2011; 15: 525-532.
43. Zhao JY, Ikeguchi M, Eckersberg T, Kuo MT,. Modulation of multidrug-resistance gene-expression by dexamethasone in cultured hepatoma-cells. Endocrinology 1993; 133: 521-528.
44. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C,. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000; 68: 356-366.
45. Kim IW, Moon YJ, Ji E, Kim KI, Han N, Kim SJ, Shin WG, Ha J, Yoon JH, Lee HS, Oh JM,. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. Eur J Clin Pharmacol 2012; 68: 657-669.